Bionano Genomics, Inc.
NASDAQ: BNGO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Robert Erik Holmlin
- Employees
- 98
- Headquarters
- San Diego, United States
- IPO year
- 2018
- Market cap
- $13.0M
- Website
- https://www.bionanogenomics.com
Loading BNGO…
Loading profile data…Frequently asked questions about BNGO
What does Bionano Genomics, Inc. (BNGO) do?
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their func...
Where does BNGO trade?
Bionano Genomics, Inc. (BNGO) trades on the NASDAQ Capital Market.
What sector is BNGO in?
Bionano Genomics, Inc. (BNGO) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Bionano Genomics, Inc.?
Robert Erik Holmlin is the chief executive officer of Bionano Genomics, Inc. (BNGO).
Where is Bionano Genomics, Inc. headquartered?
Bionano Genomics, Inc. is headquartered in United States.
Does BNGO pay a dividend?
Bionano Genomics, Inc. (BNGO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BNGO go public?
Bionano Genomics, Inc. (BNGO) completed its initial public offering in 2018.